“Increasing our capabilities in regenerative solutions is consistent with our intention to digitize, personalize and democratize oral care,” Envista CEO Amir Aghdaei said in a May 17 news release.
The transaction is subject to customary regulatory approvals but is not subject to a financing condition or shareholder vote. It is expected to close in the third quarter.
